EPGNFEpigenomics AG

About Epigenomics AG (EPGNF)

Epigenomics AG (EPGNF) is a Diagnostics & Research company headquartered in Berlin, Germany whose shares trade over-the-counter on the Pink tier.

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung, a test for lung cancer detection, and HCCBloodTest, a test for liver cancer, have received CE mark in Europe. For more information, visit www.epigenomics.com.

Products and services

--

EPGNF key facts

Ticker symbol

EPGNF

Market tier

Pink

Sector

Healthcare

Industry

Diagnostics & Research

Headquarters

Berlin, Germany

Country of incorporation

DE

Year of incorporation

1998

Employees

36

Estimated market cap

$3.21M (as of May 9, 2025)

Shares outstanding

4,066,613

Reporting standard

International Reporting: Frankfurt Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Quarterly Report (Sep 30, 2022)

Epigenomics AG leadership

• Heino von Prondzynski — Chairman of the Supervisory Board
• Gregory Hamilton — CEO
• Jens Ravens — CFO
• Andrew Lukowiak — Chief Scientific Officer
• Frederic Hilke — IR

Explore more: Diagnostics & Research stocks · Healthcare sector · Pink stocks · OTC stocks starting with E